GLP-1 diabetes drugs
Ozempic, Mounjaro, Trulicity, Victoza: weekly or daily injectables for type 2 diabetes.
2 leading companies in glp-1 diabetes drugs, one segment of pharma: glp-1 & obesity drugs — Semaglutide, tirzepatide and the next wave: about $132B in 2025 GLP-1 sales, with generics now open in Canada
new market segment · researched 2026-11-14
GLP-1 diabetes drugsWeight-loss (obesity) injectablesOral GLP-1 pillsNext-generation obesity drugsGeneric semaglutideSupply chain, compounding & pharmacy
C
Leading glp-1 diabetes drugs companies
2 companies, with the scale each source states. Scale is the whole company's unless the row says otherwise.
| Company | Where | What they do | Scale |
|---|---|---|---|
| Novo Nordisk NOVO-B.CO / NVO ↗ | Bagsværd, Denmark since 1923 | Semaglutide (Ozempic, Wegovy, Rybelsus, oral Wegovy) and liraglutide. CagriSema and amycretin in development. | revenue: 309.1 DKK billions (total company) (2025) ↗ |
| Eli Lilly and Company LLY ↗ | Indianapolis, United States since 1876 | Tirzepatide (Mounjaro, Zepbound), orforglipron pill (Foundayo) and retatrutide in Phase 3. Reached $1T market cap Nov 2025. | revenue: 65.179 USD billions (total company) (2025) ↗ |
M
The pharma: glp-1 & obesity drugs market
The whole market this segment sits in.
global revenue · world132
↗USD billions (GLP-1 therapies, all indications) · 2025
Growth, segments, risks and every company in pharma: glp-1 & obesity drugs →
Quick answers
- What are glp-1 diabetes drugs?
- Ozempic, Mounjaro, Trulicity, Victoza: weekly or daily injectables for type 2 diabetes. They are one segment of the pharma: glp-1 & obesity drugs market.
- Who are the leading glp-1 diabetes drugs companies?
- Novo Nordisk (Denmark), Eli Lilly and Company (United States).
- Which glp-1 diabetes drugs companies are publicly traded?
- Novo Nordisk (NOVO-B.CO / NVO), Eli Lilly and Company (LLY).
- How big is the pharma: glp-1 & obesity drugs market?
- For the whole pharma: glp-1 & obesity drugs market, not this segment alone: global revenue (world) 132 USD billions (GLP-1 therapies, all indications), 2025 — Managed Healthcare Executive.